Artwork

Contenido proporcionado por CommonSpirit Health Physician Enterprise. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente CommonSpirit Health Physician Enterprise o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis

5:16
 
Compartir
 

Manage episode 418455867 series 3291352
Contenido proporcionado por CommonSpirit Health Physician Enterprise. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente CommonSpirit Health Physician Enterprise o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

First-of-its-kind medication shows promise for liver disease patients

  • Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
  • The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
  • Prior to the FDA approval, there were no approved drugs to treat this disease

In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management

Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.

Study: https://www.nejm.org/doi/10.1056/NEJMoa2309000

  continue reading

106 episodios

Artwork
iconCompartir
 
Manage episode 418455867 series 3291352
Contenido proporcionado por CommonSpirit Health Physician Enterprise. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente CommonSpirit Health Physician Enterprise o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

First-of-its-kind medication shows promise for liver disease patients

  • Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
  • The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
  • Prior to the FDA approval, there were no approved drugs to treat this disease

In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management

Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.

Study: https://www.nejm.org/doi/10.1056/NEJMoa2309000

  continue reading

106 episodios

Todos los episodios

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida